Li Wang

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Mark C. Genovese, Josef S Smolen, Michael E. Weinblatt et al. · Arthritis & Rheumatology · 2016 · 199 citations · Full text

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

Joel M. Kremer, Paul Emery, Heidi S. Camp et al. · Arthritis & Rheumatology · 2016 · 173 citations · Full text

Age- and sex-related differences in body composition in healthy subjects aged 18 to 82 years

Xue He, Zishuai Li, Xunhui Tang et al. · Medicine · 2018 · 118 citations · Full text

Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy

Wenhui Wei, Keith Knapp, Li Wang et al. · Advances in Therapy · 2017 · 61 citations · Full text

Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs

Chieh-I Chen, Li Wang, Wenhui Wei et al. · Rheumatology Advances in Practice · 2018 · 59 citations · Full text